LONDON (Alliance News) - GlaxoSmithKline PLC said ViiV Healthcare Ltd, its joint venture HIV company with Pfizer Inc and Shionogi Ltd, received approval from the US Food and Drug Administration for its Triumeq HIV-1 treatment late last Friday.
The single-pill treatment combines integrase strand transfer inhibitor dolutegravir and nucleoside reverse transcriptase inhibitors abacavir and lamivudine.
"Today?s approval of Triumeq offers many people living with HIV in the US the first single-pill regimen containing dolutegravir. ViiV Healthcare is committed to delivering advances in care and new treatment options to physicians and people living with HIV," the chief executive Of ViiV Healthcare, Dominique Limet, said in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
